Catechol-O-methyltransferase and monoamine oxidase-A polymorphisms and treatment response to typical and atypical neuroleptics [5]

Journal of Clinical Psychopharmacology

Volumn 26, Issue 3, 2006, Pages 338-340

  Nolan, Karen A ^a,b   Czobor, Pál ^a,b   Citrome, Leslie L ^a,b   Krakowski, Menachem ^a,b   Lachman, Herbert M ^c   Kennedy, James L ^d   Ni, Xingqun ^d   Lieberman, Jeffrey ^e,f   Chakos, Miranda ^g   Volavka, Jan ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e Columbia University ^*  (United States)

^f NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^g SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; ATYPICAL ANTIPSYCHOTIC AGENT; CATECHOL METHYLTRANSFERASE; CLOZAPINE; HALOPERIDOL; OLANZAPINE; RISPERIDONE;

ALLELE; DISEASE SEVERITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LETTER; PHENOTYPE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROMOTER REGION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; CATECHOL O-METHYLTRANSFERASE; GENOTYPE; HUMANS; MONOAMINE OXIDASE; POLYMORPHISM, GENETIC; PSYCHOTIC DISORDERS;

EID: 33744499186     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000220526.29657.04     Document Type: Letter

References (7)

1. Lachman HM, Papolos DF, Saito T, et al. Human catechol-O- methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996;6:243-250.
2. Sabol SZ, Hu S, Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genetics. 1998;103:273-279.
3. Caspi A, McClay J, Moffitt TE, et al. Role of genotype in the cycle of violence in maltreated children. Science. 2002;297:851-854.
4. Illi A, Mattila KM, Kampman O, et al. Catechol-O-methyltransferase and monoamine oxidase A genotypes and drug response to conventional neuroleptics in schizophrenia. J Clin Psychopharmacol. 2003;23:429-434.
5. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in treatment-resistant patients with schizophrenia and schizoaffective disorder. Am J Psychiatry. 2002;159:255-262.
6. Krakowski M, Czobor P, Citrome L, et al. Atypical antipsychotic agents in the treatment of violent schizophrenic and schizoaffective patients. Arch Gen Psychiatry. 2006, in press.
7. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002;47:27-38.